Aptose reports tuspetinib CRs across 4 dose levels in r/r AML; establishes $50M ATM facility

Aptose Biosciences Inc.

Tuspetinib monotherapy yielded 38.1% response in FLT3+ and 19% in FLT3-WT r/r AML across 40-160mg doses.
Luxeptinib G3 formulation shows up to 18-fold bioavailability improvement; continuous dosing initiated in AML patients.
Aptose entered ATM equity distribution agreement with JonesTrading for up to $50M common share sales on Nasdaq.
Tuspetinib selected 120mg as monotherapy expansion dose and 80mg for venetoclax combo in APTIVATE trial.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Aptose Biosciences Inc. entered into Equity Distribution Agreement with JonesTrading Institutional Services LLC (effective 2022-12-09).

Action: entry
Agreement: atm program
Counterparty: JonesTrading Institutional Services LLC
Effective: 2022-12-09

Exact text from the filing

On December 9, 2022, Aptose Biosciences Inc. entered into an Equity Distribution Agreement (the “EDA”) with JonesTrading Institutional Services LLC, as agent, (the “Agent”) in connection with the establishment of an “at-the-market” sales facility.

View on SEC.gov

273 material agreements filed in the last 30 days. Browse all material agreements →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001171843-22-007974

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.